Why so many significant phase III results in clinical trials?
View ORCID ProfileJérôme Adda, Christian Decker, View ORCID ProfileMarco Ottaviani
doi: https://doi.org/10.1101/19001495
Jérôme Adda
†Department of Economics and IGIER, Bocconi University, Via Roberto Sarfatti 25, 20136 Milan, Italy. Phone: +39–02–5836–5572. E-mail:
Christian Decker
‡Department of Economics, University of Zurich, Schönberggasse 1, 8001 Zurich, Switzerland. Phone: +41–44– 634–61–26. E-mail:
Marco Ottaviani
§Department of Economics and IGIER, Bocconi University, Via Roberto Sarfatti 25, 20136 Milan, Italy. Phone: +39–02–5836–3385. E-mail:
Posted November 25, 2019.
Why so many significant phase III results in clinical trials?
Jérôme Adda, Christian Decker, Marco Ottaviani
medRxiv 19001495; doi: https://doi.org/10.1101/19001495
Subject Area
Subject Areas
- Addiction Medicine (354)
- Allergy and Immunology (676)
- Anesthesia (182)
- Cardiovascular Medicine (2676)
- Dermatology (227)
- Emergency Medicine (404)
- Epidemiology (12302)
- Forensic Medicine (10)
- Gastroenterology (768)
- Genetic and Genomic Medicine (4148)
- Geriatric Medicine (389)
- Health Economics (684)
- Health Informatics (2688)
- Health Policy (1009)
- Hematology (365)
- HIV/AIDS (859)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (444)
- Neurology (3930)
- Nursing (212)
- Nutrition (584)
- Oncology (2068)
- Ophthalmology (592)
- Orthopedics (243)
- Otolaryngology (307)
- Pain Medicine (252)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1128)
- Primary Care Research (461)
- Public and Global Health (6572)
- Radiology and Imaging (1418)
- Respiratory Medicine (874)
- Rheumatology (413)
- Sports Medicine (345)
- Surgery (455)
- Toxicology (54)
- Transplantation (189)
- Urology (169)